Ambrisentan

證據等級: L5

預測適應症: 10 個

Ambrisentan: From Idiopathic Pulmonary Arterial Hypertension to Connective Tissue Disease-Associated Pulmonary Arterial Hypertension

One-Sentence Summary

Ambrisentan is a selective endothelin type A (ETA) receptor antagonist originally developed for idiopathic/heritable pulmonary arterial hypertension (PAH). The TxGNN model — together with corroborating clinical and literature evidence — predicts it may also be effective for Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH), with 3 clinical trials (including the pivotal AMBITION combination-therapy program) and 20 publications, including a systematic review and meta-analysis, currently supporting this direction.

Note on indication selection: This Evidence Pack contains 10 TxGNN-predicted indications for ambrisentan. The single highest-scoring prediction by raw TxGNN score (pulmonary arteriovenous malformation, 99.41%) is supported by only one case report and is scored L4/Hold by the pipeline's own evidence engine. This report instead focuses on CTD-PAH, which carries the strongest, most clinically actionable evidence body among the ten candidates (L1, decision stage S3, "Proceed with Guardrails"). A full screening summary of all 10 candidates is provided at the end of this report for transparency.

Quick Overview

Item	Content
Original Indication	Idiopathic / Heritable Pulmonary Arterial Hypertension (WHO Group 1 PAH) — inferred from cross-referenced literature and mechanistic rationale, since Germany license records returned zero entries
Predicted New Indication	Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH)
TxGNN Prediction Score	99.30%
Evidence Level	L1
Germany Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed structured mechanism-of-action data was not returned by the DrugBank query (flagged as a High-severity data gap). However, the mechanistic rationale is consistently documented across the Evidence Pack's repurposing analyses: Ambrisentan is a selective endothelin type A (ETA) receptor antagonist. By blocking endothelin-1-mediated vasoconstriction and vascular smooth muscle proliferation, it reduces pulmonary vascular resistance and reverses pathological pulmonary vascular remodeling — the shared final pathway of all WHO Group 1 PAH subtypes.

Connective tissue disease-associated PAH (most commonly seen in systemic sclerosis/scleroderma, and also lupus and mixed connective tissue disease) is classified as WHO Group 1.4.1 — a molecularly indistinguishable process from idiopathic PAH, differing only in the upstream autoimmune trigger that initiates endothelial injury and endothelin-1 overexpression. Because the terminal vascular pathology and drug target are identical, ETA-receptor blockade is mechanistically as applicable in CTD-PAH as in idiopathic PAH.

This mechanistic plausibility is strongly reinforced by real clinical precedent already present in the literature: a 2017 review (PMID 28425346) explicitly states that ambrisentan is "approved for the treatment of idiopathic, heritable PAH and connective tissue disease-associated PAH." Multiple post-hoc/subgroup analyses of the AMBITION trial — ambrisentan's own pivotal registration study, combined with tadalafil — specifically evaluated the CTD-PAH subpopulation and reported meaningful benefit, further supporting that the TxGNN prediction reflects an indication already partially validated in real-world regulatory and clinical practice elsewhere, rather than a purely speculative extrapolation.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01042158	Phase 4	Completed	25	Open-label study of ambrisentan + tadalafil combination therapy in PAH associated with systemic sclerosis spectrum disease (PAH-SSD); assessed 6MWD, NYHA class, and hemodynamics.
NCT02290613	Phase 2	Completed	38	EDITA proof-of-concept RCT: early ambrisentan treatment in borderline/early elevated pulmonary artery pressure associated with systemic sclerosis.
NCT02885012	Phase 4	Terminated (n=3)	3	Switch study from bosentan/macitentan to ambrisentan in CTD-PAH; terminated early due to low enrollment, safety-observation value only.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
38378970	2024	Systematic Review & Meta-analysis	Internal and Emergency Medicine	Pooled RCT evidence for CTD-PAH treatment outcomes (functional class, survival, 6MWD, NT-proBNP).
23906950	2013	Meta-analysis	BMJ Open	Meta-analysis of clinical trials establishing efficacy signal for PAH-targeted therapy, including ambrisentan, in CTD-PAH.
26360334	2015	RCT (AMBITION subgroup)	American Journal of Respiratory and Critical Care Medicine	Up-front ambrisentan + tadalafil combination therapy in scleroderma-associated PAH (SSc-PAH).
31655622	2019	RCT (EDITA study)	Arthritis Research & Therapy	Randomized, double-blind, placebo-controlled trial of early ambrisentan in mildly elevated mPAP associated with systemic sclerosis.
32161055	2020	Cohort (AMBITION post-hoc)	Annals of the Rheumatic Diseases	Post-hoc analysis of initial ambrisentan + tadalafil combination therapy in CTD-PAH within the AMBITION modified ITT population.
28039187	2017	Cohort (AMBITION subgroup)	Annals of the Rheumatic Diseases	Subgroup analysis of AMBITION trial confirming benefit of initial combination therapy in CTD-PAH, including systemic sclerosis.
27492539	2016	Cohort (ARIES-E subgroup)	Respiratory Medicine	3-year efficacy and safety of ambrisentan specifically in CTD-PAH patients from the ARIES-E extension study.
29282676	2018	Post-marketing Surveillance	Clinical Drug Investigation	Real-world safety and efficacy surveillance of ambrisentan (Volibris) in 702 PAH patients, including CTD-associated cases.
28425346	2017	Review	Therapeutic Advances in Respiratory Disease	States ambrisentan is approved for idiopathic/heritable PAH and CTD-PAH; summarizes efficacy on exercise capacity and hemodynamics.
37765060	2023	Review	Pharmaceuticals (Basel)	Recent advances in treatment of PAH associated with connective tissue disease, contextualizing ERA therapy including ambrisentan.

Germany Market Information

No marketing authorizations are currently on record — ambrisentan is not marketed in this jurisdiction per the available regulatory data (0 licenses).

Safety Considerations

Please refer to the package insert for safety information. The Evidence Pack's German regulatory warnings/contraindications and drug-drug interaction (DDI) database queries did not return usable data (DDI query status: not found; package insert data flagged as a Blocking data gap, DG001), so no drug-specific warnings can be cited here beyond the general PAH-therapy class considerations (e.g., hepatic monitoring, teratogenicity, fluid retention typical of endothelin receptor antagonists) — none of which are sourced from this Evidence Pack and should not be treated as a substitute for the official label.

Other TxGNN-Predicted Indications (Screening Summary)

For transparency, given this Evidence Pack evaluated 10 candidate indications for ambrisentan, the table below summarizes how each was scored so the choice of CTD-PAH as the lead indication in this report can be cross-checked:

Rank	Predicted Indication	TxGNN Score	Evidence Level	Recommendation
1	Pulmonary arteriovenous malformation	99.41%	L4	Hold — mechanistically distinct (structural shunt vs. endothelin-driven vasculopathy); only 1 case report
2	PAH associated with congenital heart disease	99.37%	L1	Proceed with Guardrails — 9 trials incl. a completed Phase 3b (134 pts); strong mechanistic overlap (WHO Group 1.4.4)
3	PAH associated with schistosomiasis	99.30%	L5	Hold — no trials or literature; pure mechanistic extrapolation
4	PAH associated with HIV infection	99.30%	L1	Proceed with Guardrails — 1 completed Phase 3 RCT (64 pts) + 4 supporting papers; requires antiretroviral DDI guardrails
5	PAH associated with connective tissue disease (this report)	99.30%	L1	Proceed with Guardrails — strongest evidence body (AMBITION subgroup, meta-analysis, systematic review); precedent of approval elsewhere
6	PAH associated with chronic hemolytic anemia	99.30%	L5	Hold — no trials or literature; theoretical mechanistic link only
7	Malformation syndrome with odontal/periodontal component	99.19%	L5	Hold — retrieved literature is unrelated periodontitis research; likely embedding-similarity false positive
8	Hypotrichosis simplex of the scalp	99.15%	L5	Hold — no mechanistic basis, no evidence; model noise
9	Hypertrichosis	99.14%	L5	Hold — no mechanistic basis (ETA antagonism ≠ minoxidil-type mechanism); model noise
10	Syndrome with Dandy-Walker malformation as major feature	99.12%	L5	Hold — no mechanistic basis; likely keyword ("malformation") similarity artifact

This confirms that ambrisentan's genuinely repurposable candidates cluster tightly around other PAH etiological subtypes (ranks 2, 4, 5), consistent with its known ETA-antagonist mechanism, while the remaining candidates are either single-case anecdotal signals or apparent embedding-similarity noise unrelated to the drug's pharmacology.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: CTD-PAH is supported by L1-level evidence — including subgroup analyses from ambrisentan's own pivotal AMBITION trial, a dedicated meta-analysis, and a systematic review — and the mechanism (ETA-receptor antagonism against endothelin-driven vascular remodeling) is pathophysiologically identical to the drug's original PAH indication. Literature further indicates ambrisentan is already approved for CTD-PAH in other markets. However, the drug currently has zero marketing authorizations in this jurisdiction and critical safety documentation (package insert warnings/contraindications, DDI data) is missing, which prevents this from being a clean "Go."

To proceed, the following is needed:

Obtain the official German/local package insert (warnings, contraindications) — currently a Blocking data gap (DG001)
Formally resolve the detailed mechanism-of-action documentation via DrugBank API rather than relying on inferred rationale text (High-severity gap, DG002)
Conduct a dedicated DDI database review, since the current query returned no results
Clarify local regulatory pathway/status, given the drug is currently unlicensed and unmarketed here (0 authorizations)
Consider parallel evaluation of PAH-associated congenital heart disease and PAH-associated HIV infection (ranks 2 and 4), which also scored L1/"Proceed with Guardrails" and may support a broader repurposing label strategy across PAH subtypes
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.